原发性血小板增多症(primary thrombocytosis)是一种病因未明,主要以骨髓中巨核细胞系异常增生,幼稚巨核细胞增多,从而产生大量形态及功能异常的血小板释放至血液循环中,导致以出血和血栓形成为主要特征的罕见疾病[1]。脾大、出血或血栓形成为其主要临床表现[2],而以急性心肌梗死为首发临床表现的则少见,其致死风险高。由于其具有出血及血栓形成双重风险,给临床抗栓治疗 Primary thrombocytosis is an unknown etiology, mainly in the abnormal proliferation of megakaryocyte cells in the bone marrow, immature megakaryocytes increased, resulting in a large number of morphologically and functionally abnormal release of platelets into the bloodstream, resulting in bleeding and Thrombosis as the main characteristic of rare diseases [1]. Splenomegaly, bleeding or thrombosis as its main clinical manifestations [2], while the clinical manifestations of acute myocardial infarction as the first is rare, the high risk of lethal. Due to its dual risk of bleeding and thrombosis, clinical antithrombotic therapy is given